TABLE 2.
Susceptibility profile of ESBL-E. coli carriage isolates from Tromsø7 (n = 166) and clinical isolates from NORM 2014 (n = 118) d
| Carriage | Clinical | |||||
|---|---|---|---|---|---|---|
| %S | %I | %R | %S | %I | %R | |
| Amoxicillin–clavulanic acid i.v. | 57.2 | – | 42.8 | 25.4 | – | 74.6 |
| Amoxicillin–clavulanic acid a | 90.4 | – | 9.6 | 54.2 | – | 45.8 |
| Piperacillin–tazobactam | 97.6 | – | 2.4 | 68.2 b | – | 31.8 b |
| Cefuroxime a | 0.6 | – | 99.4 | 1.7 | – | 98.3 |
| Ceftazidime | 20.5 | 32.5 | 47.0 | 10.2 | 11.0 | 78.8 |
| Cefotaxime | 0.0 | 2.4 | 97.6 | 0.8 | 0.8 | 98.4 |
| Cefepime | 7.8 | 54.8 | 37.3 | 4.7 b | 5.9 b | 89.4 b |
| Ceftazidime–avibactam | 100.0 | – | 0.0 | NA | NA | NA |
| Ertapenem | 100.0 | – | 0.0 | NA | NA | NA |
| Meropenem | 100.0 | 0.0 | 0.0 | 99.2 | 0.8 | 0.0 |
| Aztreonam | 5.4 | 23.5 | 71.1 | NA | NA | NA |
| Amikacin | 100.0 | – | 0.0 | NA | NA | NA |
| Gentamicin | 80.1 | – | 19.9 | 48.3 | – | 51.7 |
| Tobramycin | 76.5 | – | 23.5 | NA | NA | NA |
| Ciprofloxacin | 49.4 | 13.9 | 36.7 | 14.4 | 8.5 | 77.1 |
| Trimethoprim–sulfamethoxazole | 48.8 | 0.6 | 50.6 | 27.1 | 0.0 | 72.9 |
| Nitrofurantoin | 99.4 | – | 0.6 | 93.9 c | – | 6.1 c |
| Fosfomycin | 99.4 | – | 0.6 | NA | NA | NA |
| Fosfomycin a | 96.4 | – | 3.6 | NA | NA | NA |
| Colistin | 98.8 | – | 1.2 | NA | NA | NA |
| Tigecycline | 100.0 | – | 0.0 | 100.0 b | – | 0.0 b |
a
Breakpoints for uncomplicated urinary tract infections.
b
Available for blood culture isolates only (n = 85).
c
Available for urine culture isolates only (n = 33).
d
S, susceptible; I, susceptible, increased exposure; R, resistant; i.v., intravenous; –, no I category; NA, not available.